Blinking News’ Post

Future Pharma Companies will be Data Science Companies that also sell medicine Sanofi's €400 million investment to expand its Global Capability Centre (GCC) in Hyderabad, India, highlights the increasing importance of data and technology in the pharmaceutical industry. By onboarding talent at the Hyderabad hub to embrace the power of AI, Sanofi is positioning itself as a data-driven company that also sells medicines Sanofi's ambition to be the "first biopharma company powered by Artificial Intelligence (AI) at scale" suggests that future pharmaceutical companies will need to embrace data and technology to remain competitive

Digital Transformation: Ireland's Life Sciences on the Brink of Innovation 🌐💊 Damian Costello of Expleo Group highlights a pivotal moment for Ireland's life sciences sector, as the integration of technologies like AI beckons a new era of digital transformation. With major players having significant operations in Ireland, including Novartis, AbbVie, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer, Sanofi, Eli Lilly and Company, AstraZeneca, the move towards digitisation is seen not just as a step forward but as a necessary evolution to maintain a competitive edge on a global scale. 🇮🇪🔍 This transformation, while offering immense potential for efficiency and innovation, also presents challenges. The balance lies in enhancing production without losing the unique strengths that have made Ireland a powerhouse in life sciences. Focusing on R&D and leveraging digital health advancements, Ireland is poised to lead in personalised healthcare, transforming from traditional to digital with agility and foresight. The digital transformation heralded by Expleo's Damian Costello marks a pivotal moment for the life sciences in Ireland, a narrative Hanley Automation is strongly aligned with. 🚀🧬 #LifeSciences #DigitalTransformation #IrelandInnovation #Expleo #HanleyAutomation

We asked over 40,000 people in 13 different countries which #pharmaceutical companies they trust and like the most. Here are the results ⤵ 1. Roche With a legacy spanning 125 years, Roche is celebrated for its groundbreaking advancements in biotech and in-vitro diagnostics. Their steadfast focus on improving patient outcomes by providing access to cutting-edge healthcare worldwide has solidified their reputation. Roche excels in forging strong partnerships with governments and local stakeholders to build resilient healthcare systems, especially in underserved regions, making a profound global impact. 2. Novartis stands out for its relentless innovation in medicine, improving and extending the lives of over 250 million people worldwide. Operating over 30 production sites, Novartis ensures a reliable supply of medicines while also focusing on affordability and sustainability. Their transparent ESG initiatives and collaborative efforts with patient communities and healthcare professionals underscore why they are highly trusted and liked. 3. GSK's ambition to positively impact the health of 2.5 billion people by the decade’s end reflects their strong commitment to public health. GSK leads the charge in addressing critical global health issues, such as antimicrobial resistance and pandemic threats. Their forward-thinking initiatives not only enhance long-term health security but also reinforce the confidence and trust of their stakeholders. 4. Bayer's mission, “Health for all, Hunger for none,” drives their innovative and ethical approach to healthcare and agriculture. Known for their impactful contributions across pharmaceuticals, consumer health, and crop science, Bayer’s focus on sustainability and social responsibility is commendable. Bayer stands out with its dynamic approach, empowering employees to drive innovation and consistently delivering value to customers and stakeholders. 5. Johnson & Johnson's patient-centered innovations in therapeutic areas such as oncology and immunology demonstrate their commitment to tackling complex diseases. Their emphasis on high-quality, affordable healthcare, combined with strong support for diversity and inclusion, resonates deeply with stakeholders. J&J’s extensive global partnerships and initiatives to support underserved communities further solidify their position as a trusted and liked company. 🎉 Congratulations to these exceptional companies. Your dedication to innovation, ethical practices, and community support is has not gone unnoticed. 🔗 Read the full report here: https://lnkd.in/dHYEWvsy #Pharma #ReputationExcellence #globalpharma #bigpharma #pharmasector

We're looking forward to returning to the #LogipharmaConnect conference, November 20-21 in Montreux, Switzerland. Join us to hear Jason Lacombe, CEO at Veratrak, who will lead a panel discussion on Wednesday 20th November at 15:10: "How can you work with partners to develop end-to-end digital ecosystems that drive efficiencies, agility and resilience?", joined by senior industry experts from AbbVie, AstraZeneca, Amgen and BD. #supplychainsoftware

Strategic Pharma Product Launches in India: A Deep Dive Using the AARRR Framework 🚀 Successfully launching a pharmaceutical product, especially in a complex market like India, demands a strategic approach. In my latest Medium post, I explore how the AARRR framework (Acquisition, Activation, Retention, Referral, Revenue) can be applied to drive market penetration, foster relationships with key stakeholders, and ultimately enhance patient outcomes. This framework, tailored for the Indian pharmaceutical landscape, is particularly relevant for launching innovative cancer treatments. Key Highlights: Acquisition: Targeting HCPs and patients through data-driven campaigns. Activation: Leveraging demographic-specific data and AI-driven patient support. Retention: Continuous education and personalized engagement to ensure adherence. Referral: Creating advocates through success stories and referral programs. Revenue: Implementing value-based pricing strategies to ensure accessibility and sustainability. 👉 Read the full post here: https://lnkd.in/g56kmwB9 💡 How can we adapt these strategies to better navigate India’s unique healthcare challenges? #PharmaProductManagement #StrategicFrameworks #AARRR #ProductLaunch #CancerTreatment #HealthcareInnovation #PatientOutcomes

Over the past decade, clinical trials in India have become easier and faster, attracting more multinational companies. From 2017 to 2023, phase two and three trials in India have grown by 15-18%. This growth is due to 10 key modifications to the Drugs and Cosmetics Act of 1940, aiming to simplify and speed up the trial process. Badhri Srinivasan, Head, Global Development Operations at Novartis, highlighted these changes at the 18th Annual BioPharma & Healthcare Summit in Boston, organized by the USA India Chamber of Commerce. India's clinical trial landscape has historically faced challenges, including perceptions of slow processes and burdensome timelines. Christopher Corsico, Senior Vice President, Head of Development at GSK, noted that while there were difficulties in including India early in global trials, improvements have led to a reduction in timelines by 30-40%. He emphasized that involving India strategically can yield significant benefits, such as reducing the need for phase four studies if a large enough subpopulation is included in phase three data. Uli Broedl, Head of Global Clinical Development & Operations at Boehringer Ingelheim, echoed these sentiments, stating that India now presents substantial opportunities. He dismissed the misconception of poor quality, highlighting that infrastructure has improved significantly, resulting in faster approval timelines for clinical trial applications. To further enhance its role in global clinical trials, India must focus on developing market access pathways and improving regulatory transparency. By fostering collaboration between pharmaceutical companies and local stakeholders, India can better navigate the complexities of drug development and ensure that innovative therapies reach patients more efficiently.    #ClinicalTrials #DrugDevelopment #MedicalResearch #LifeSciences #India 

Our 3rd edition of the Pharmaceutical Digital Health Innovation Index 2024 is here! In this comprehensive report we evaluate the Digital Health portfolios of pharmaceutical and biotech companies, focusing on the strength of their ventures and alignment with strategic goals. 📌 Why this report matters now 2024 marks a significant evolution in biopharma’s approach to digital health. What began as pilot projects and innovation labs has matured into strategic execution. Today, the question is no longer "if" digital health delivers value but "how" to integrate and scale these technologies for measurable impact. 💡 Focus areas: Strength and alignment of Digital Health venture portfolios with strategic objectives. Transition from experimental pilots to scalable execution. AI and generative AI in drug discovery, clinical trials, and patient-centric solutions. Partnerships advancing drug accessibility, patient adherence, and engagement. 📈 Insights from the report: The adoption of Digital Health is expanding across the biopharma ecosystem. In 2021, the top 25 biopharma firms held 57% of global digital health partnerships. By 2024, this share dropped to 42%—indicating increased participation by a broader range of companies. AI dominance: Since 2020, 72% of digital health ventures partnering with biopharma utilize AI or generative AI, driving efficiencies in drug discovery and enabling personalized care. In 2024, firms like Eli Lilly and Company, Pfizer, and Astellas Pharma launched direct-to-patient platforms integrating telehealth, online pharmacies, and disease management, with 36% of partnerships centered on patient-centric innovations.

🔥 GSK transforms patient experience through tech with adesso 🤝   London, June 2024: GSK, a leading UK based biopharmaceutical company, has transformed its patientcare experience by working with adesso, the global technology consultancy. They needed a system in place to support patients during their treatment cycle. With thousands of patients around the globe in need of regular updates, it was critical do offer a solution that is nimble-easy to execute and impactful in patients’ lives. Working with adesso, the team developed the DREAM project, providing patients with personalised communications and reminders to improve their adherence to vaccines and medication. The new project has already been successfully rolled out to five key markets, with a further 10-15 on the way. Necati Sebe, Head of Commercial Operations and Strategy at GSK: “One of our key reasons for existence is 'Being Impactful for Patients.' DREAM project is our revolutionary idea on helping patients improve their adherence to medicine and vaccines. We chose Adesso because of their expertise, agile approach to project management, and flexibility. This was needed as we were constantly learning and adapting to changing priorities. Their team was always willing to go the extra mile to find the best fitting solutions to even the most complex challenges, it’s harder to make things easier, and with this partnership, we achieved that.”   Libero Raspa, Managing Director of adesso UK, comments: “They are a fantastic brand which needed a digital solution that could completely transform its patientcare services. Having a customer-centric approach means prioritising user experience and ease of use at every stage of development within the process. Our agile methodology during development allowed for continuous communication and rapid problem-solving.” Business success is the result of innovative ideas, forward-looking strategies and perfectly tailored IT solutions that provide optimal support to companies as they face their own particular challenges. This always involves the contribution of people who bring the right mix of technological expertise and a deep understanding of the customer’s particular business. With a team of more than 10.000 employees on over 64 sites within the adesso Group, they are one of the leading IT service providers in continental Europe. adesso works every day to successfully implement their customers' projects. #PatientCare #HealthcareInnovation #DigitalTransformation #GSK #adesso #DREAMProject #HealthcareTechnology #AgileDevelopment

Credit to Thomas Hagemeijer September , 2024 Pfizer has just launched a new direct-to-consumer virtual service called PfizerForAll, following a similar initiative by Eli Lilly in January. https://lnkd.in/grjcQXe9 1️⃣ 𝐖𝐡𝐲 𝐢𝐬 𝐏𝐟𝐢𝐳𝐞𝐫 𝐥𝐚𝐮𝐧𝐜𝐡𝐢𝐧𝐠 𝐚 𝐃𝟐𝐂 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦? 𝐁𝐞𝐜𝐚𝐮𝐬𝐞 𝐨𝐟 𝐦𝐚𝐜𝐫𝐨 𝐭𝐫𝐞𝐧𝐝𝐬, 𝐛𝐫𝐚𝐧𝐝 𝐞𝐪𝐮𝐢𝐭𝐲, 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐚𝐜𝐜𝐞𝐬𝐬 𝐚𝐧𝐝 𝐛𝐚𝐫𝐠𝐚𝐢𝐧𝐢𝐧𝐠 𝐩𝐨𝐰𝐞𝐫. Macro Trends: ➡️ Certain consumer segments prefer telehealth for specific use cases, some of which align with Pfizer's portfolio. ➡️ Additionally, too many intermediaries are taking a share of the profits in the US market. Pfizer can "cut the middlemen" by selling directly to patients. Brand Equity: ➡️ Pfizer is “trying to leverage some of that brand equity that they got the world spinning again (during Covid)”, said Markus Saba, a marketing professor at the University of North Carolina Center. Patient access: ➡️ With a modest investment and minimal risk, Pfizer can open this new channel to engage directly with patients. Bargaining power: ➡️ It is a new path to market that gives Pfizer more leverage when it comes to negotiating with payers. 2️⃣ 𝐓𝐡𝐞 𝐬𝐮𝐜𝐜𝐞𝐬𝐬 𝐨𝐟 𝐇𝐢𝐦𝐬 & 𝐇𝐞𝐫𝐬 𝐦𝐮𝐬𝐭 𝐡𝐚𝐯𝐞 𝐢𝐧𝐬𝐩𝐢𝐫𝐞𝐝 𝐏𝐟𝐢𝐳𝐞𝐫 Hims & Hers has a $3.2B market cap, and its stock increased by almost 50% since it went public in January 2021. Ironically, Hims & Hers initially gained attention by offering generic versions of Viagra, which was the blockbuster product of Pfizer. In a way, Pfizer is getting its revenge today: Hims & Hers stock has dropped 15% since the announcement of PfizerforAll, as investors fear increased competition. 3️⃣ 𝐏𝐟𝐢𝐳𝐞𝐫 𝐢𝐬 𝐰𝐢𝐥𝐥𝐢𝐧𝐠 𝐭𝐨 𝐛𝐮𝐢𝐥𝐝 𝐚𝐧 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐚𝐫𝐨𝐮𝐧𝐝 𝐢𝐭𝐬 𝐢𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 The "unfair advantage" of Pfizer in migraines, COVID-19, flu and vaccines is in its treatments. Pfizer therefore thinks it can build an ecosystem for these indications: PfizerForAll was launched in partnership with several healthcare organizations, including UpScriptHealth, Alto Pharmacy and Instacart. 4️⃣ 𝐀 𝐔𝐒 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡, 𝐧𝐨𝐭 𝐫𝐞𝐚𝐥𝐥𝐲 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐛𝐥𝐞 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 In the U.S., the "out-of-pocket" market accounts for $500 billion out of the total $4 trillion+ healthcare market. To put that in perspective, $500 billion is equivalent to the size of Germany's healthcare market, the largest in Europe. As a result, there is far more "consumerization of hashtag#healthcare" in the U.S. compared to Europe, creating opportunities for initiatives like PfizerforAll. In the US, consumers are often required to make personal decisions about their healthcare, whereas in Europe’s universal health systems, most decisions are made upfront by public payors.